Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study-Reference-Cited by-同舟云学术

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Published:2011-08 Issue:8 Volume:12 Page:735-742
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Zhou Caicun,Wu Yi-Long,Chen Gongyan,Feng Jifeng,Liu Xiao-Qing,Wang Changli,Zhang Shucai,Wang Jie,Zhou Songwen,Ren Shengxiang,Lu Shun,Zhang Li,Hu Chengping,Hu Chunhong,Luo Yi,Chen Lei,Ye Ming,Huang Jianan,Zhi Xiuyi,Zhang Yiping,Xiu Qingyu,Ma Jun,Zhang Li,You Changxuan

Publisher

Elsevier BV

Subject

Oncology

Reference20 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

2. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

3. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study;Giaccone;Clin Cancer Res,2006

4. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer;Jackman;J Clin Oncol,2007

5. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

Cited by 3515 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer;Translational Oncology;2024-11

2. Optical functional nanomaterials for cancer photoimmunotherapy;Coordination Chemistry Reviews;2024-10

3. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysis;2024-09-11

4. Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine;Life;2024-09-10

5. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study;Journal of Clinical Oncology;2024-09-10